Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart failure drug tested in 2,400 chinese patients

NCT ID NCT05728502

Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collected data from 2,400 adults in China with chronic heart failure to see how well the drug vericiguat works compared to standard treatments. Researchers tracked deaths, hospital stays, and side effects over 12 months. The goal is to understand if vericiguat helps control the disease better in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,400 people

The number who actually took part.

Started

Apr 2023

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is composed of Chinese adult HFrEF patients who are prescribed vericiguat or standard treatment by the physician.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: vericiguat arm * Female and male patients ≥ 18 years of age who are naïve to vericiguat treatment * Patients with HFrEF after a recent decompensation episode (within 6 months of heart failure hospitalization or within 3 months of intravenous (IV) diuretics for heart failure not requiring hospitalization) * Decision to initiate treatment with vericiguat as per the local approved label * Signed informed consent control arm * Aged 18 or over at baseline * Only patients receiving SoC for chronic heart failure (no history of receiving vericiguat prior to the index date) * Patients with HFrEF after a recent decompensation episode (within 6 months of heart failure hospitalization or within 3 months of intravenous (IV) diuretics for heart failure not requiring hospitalization) Exclusion Criteria: vericiguat arm * Participation in other investigational program with interventions outside of routine clinical practice * Contra-indications according to the local marketing authorization label control arm * Patients who have started therapy with vericiguat for chronic heart failure at baseline * Contra-indications according to the vericiguat local marketing authorization label * Patients participating in an interventional study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic heart failure with reduced ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic heart failure with reduced ejection fraction

Contacts and locations

Locations

  • Chinese Registries

    Multiple Locations, Many Locations, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.